Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 176373, 8 pages
http://dx.doi.org/10.1155/2015/176373
Research Article

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy

1Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center, Peking University, Beijing 100034, China
2Department of Orthopedics, Peking University First Hospital, Beijing 100034, China
3Department of Thoracic Surgery, Peking University First Hospital, Beijing 100034, China

Received 14 June 2015; Revised 5 August 2015; Accepted 13 August 2015

Academic Editor: Andrea Minervini

Copyright © 2015 Xiaoteng Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To investigate the efficacy of surgery in the treatment of metastatic renal cell carcinoma (mRCC) and to identify prognostic factors. Methods. A single center retrospective study of 96 patients with mRCC from December 2004 to August 2013. Results. The median follow-up time was 45 months. Thirty-one (32.3%) of the patients received complete resection of metastatic sites, 11 (11.5%) of the patients underwent incomplete resection of metastatic sites, and 54 (56.3%) of the patients received no surgery. In the univariate Kaplan-Meier analysis, the median overall survival times of the three groups were 52 months, 16 months, and 22 months, respectively (). The difference in the overall survival time was statistically significant between complete resection and no surgery groups (HR = 0.43, ), while there was no significant difference between the incomplete metastasectomy and no surgery groups (HR = 1.80, ). According to the multivariate Cox regression analysis, complete metastasectomy (HR = 0.49, ), T stage > 3 (HR = 1.88, ), disease free interval <12 months (HR = 2.34, ), and multiorgan involvement (HR = 2.00, ) were significant prognostic factors. Conclusion. In the era of targeted therapy, complete metastasectomy can improve overall survival. Complete metastasectomy, T stage > 3, disease free interval <12 months, and multiorgan involvement are independent prognostic factors.